Corona Remedies Stock Jumps 11% After Strong Q4 Earnings and Strategic Acquisition

Synopsis: Pharma stock surged 11.29 percent after strong Q4 results and a strategic acquisition, supported by 20.2 percent revenue growth and 43.7 percent PAT growth.

The share of this company, which is a prominent India-based pharmaceutical company that focuses on developing, manufacturing, and marketing branded formulations, gained investor traction after posting Q4 results

With a market capitalization of Rs 10,453 crore, Corona Remedies Ltd’s share price on Tuesday hit a day high of Rs 1,951.30 per share, up by 11.29 percent from its previous day’s close of Rs 1753.20  per share. The share of this company has given a return of 24 percent since its listing in December 2025.

Results Overview & Dividend Announcement

QoQ View: The revenue from operations grew by 3.2 percent to Rs 353 crore in Q4 FY26 from Rs 342 crore in Q3 FY26 (Dec 2025). However, EBIDT saw a decline of 25.5 percent to Rs 62.0 crore from Rs 83.2 crore in the previous quarter. Despite the lower EBIDT, net profit increased by 9.2 percent to Rs 45.0 crore from Rs 41.2 crore, which led to an EPS improvement of 9.3 percent to Rs 7.37 per share from Rs 6.74 in Q3 FY26.

YoY View: The revenue from operations grew by 20 percent to Rs 353 crore in Q4 FY26 (Mar 2026) from Rs 294 crore in Q4 FY25 (Mar 2025), and EBIDT grew by 14 percent to Rs 62.0 crore in Q4 FY26 from Rs 54.2 crore in Q4 FY25. Accompanied by a net profit growth of 44 percent to Rs 45.0 crore in Q4 FY26 from Rs 31.3 crore in Q4 FY25, resulting in an EPS growth of 44 percent to Rs 7.37 per share in Q4 FY26.

Fiscal year comparison: Revenue from operations rose to Rs 1,403 crore in FY26 from Rs 1,196 crore in FY25, a growth of 17.3 percent. Operating margin improved to 21 percent in FY26 from 20 percent in FY25, reflecting a 1 percentage point increase. Profit before tax increased to Rs 240 crore in FY26 from Rs 198 crore in FY25, up 21.2 percent, while net profit rose to Rs 185 crore in FY26 from Rs 149 crore in FY25, a growth of 24.2 percent. 

Dividend: The company has recommended a final dividend of Rs 10 per equity share, representing 100 percent of the face value of Rs 10 per share for FY25-26, subject to shareholder approval at the ensuing AGM. The record date has been fixed as June 19, 2026 to determine eligibility for the dividend. If approved, the dividend will be paid on or before August 7, 2026, after applicable tax deduction at source. 

Q4 Business Performance

Revenue and Profitability Growth CORONA Remedies Limited delivered strong performance in Q4FY26 and FY26, with revenue growing 20.2 percent and 17.3 percent respectively, driven by focused brand-building initiatives. Profitability also improved sharply, with PAT rising 43.7 percent in Q4FY26 and 33.4 percent in FY26, supported by operating leverage and cost optimisation.

Strategic Expansion and Brand Strength The company strengthened its growth platform through acquisition of WOKADINE, marking entry into the Rs 648 crore Povidone Iodine market, funded via internal accruals. It also relaunched key brands in women’s health and cardiovascular segments, expanded into infertility, achieved two brands crossing Rs 100 crore MAT revenue, and improved its industry ranking to 27th in India.

Strategic Acquisitions and Portfolio Expansion The company strengthened its portfolio through the acquisition of WOKADINE, marking entry into the Rs 648 crore Povidone Iodine market. The company also expanded its branded offerings by leveraging the Bayer-Zydus portfolio through relaunch of key products, enhancing its addressable market and product depth.

Market Positioning and Operational Strength The company improved its industry ranking to 27th from 32nd over the past three years, supported by consistent execution. Chronic therapies remained a key driver, contributing around 72.3 percent in Q4FY26 and 71.9 percent in FY26, while EAEU-GMP certification further enabled expansion into multiple international markets, including Russia and CIS regions.

Management Outlook: Mr. Nirav K. Mehta, Managing Director and CEO of CORONA Remedies Limited, stated that FY26 was a strong year marked by consistent revenue growth and improved operational efficiency. He highlighted that the company’s focus on brand building, specialty segments such as biosimilars and infertility, and portfolio expansion through acquisitions continues to strengthen its competitive position.

He also noted that strategic initiatives like the WOKADINE acquisition and global accreditations position the company well for sustainable growth in the coming years.

About the Company

Founded in 2004, CORONA Remedies Limited is a leading India-focused pharmaceuƟcal company engaged in developing, manufacturing, and markeƟng products across key therapeuƟc areas including women’s healthcare, cardio-diabetes, pain management, and urology. The company operates WHO-GMP/EU GMP-cerƟfied manufacturing faciliƟes and maintains strong innovaƟon capabiliƟes through DSIR-approved R&D centers. 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Corona Remedies Stock Jumps 11% After Strong Q4 Earnings and Strategic Acquisition appeared first on Trade Brains.